{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:11:34Z","timestamp":1790615494758,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFC2704400"],"award-info":[{"award-number":["2022YFC2704400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) for patients with partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer were recruited in this prospective, open-label, single-arm, multicenter study. Eligible patients were given 4-6 cycles of PLD (40\u00a0mg\/m2 on day 1, every 4 weeks). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life, and safety. Exploratory endpoints included the change trend of CA125 and platinum-free interval.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between June 2017 and November 2020, 167 eligible patients were included in the full analysis set. The median PFS and OS were 6.8 months (95% CI, 4.4-9.3 months) and 19.1 months (95% CI, 15.0-23.3 months), respectively. The ORR and DCR were 32.3% and 60.5%, respectively. The ORR (62.3 vs 22.5%) and DCR (84.9 vs 60.7%) of patients with a CA125 decrease after the first cycle were significantly higher than those without a CA125 decrease (all P\u2005&amp;lt;\u2005.05). Grade\u2005\u2265\u20053 and serious adverse events were reported in 9.9% and 3.9% of patients, respectively. No treatment-related death was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PLD showed promising efficacy and manageable tolerability in patients with partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer.<\/jats:p>\n                  <jats:p>ClinicalTrials.gov Identifier: Chinese Clinical Trial Registry, ChiCTR1900022962.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae194","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T12:59:29Z","timestamp":1730725169000},"source":"Crossref","is-referenced-by-count":5,"title":["Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study"],"prefix":"10.1093","volume":"30","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking Union Medical College Hospital , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking Union Medical College Hospital , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Sichuan Cancer Hospital , Chengdu ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Cancer Hospital of Shandong First Medical University , Jinan ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Hua","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Second Hospital of Jilin University , Changchun ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Jiangsu Province Hospital , Nanjing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Guang","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Chinese People\u2019s Liberation Army General Hospital , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Fudan University Shanghai Cancer Center , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, The First Hospital of Jilin University , Changchun ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Henan Cancer Hospital , Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Yantai Yuhuangding Hospital , Yantai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Zhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Shandong Provincial Hospital , Jinan ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Tianjin Cancer Hospital of Gynecology Obstetrics , Tianjin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynecology II, Shanxi Cancer Hospital , Taiyuan ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Shi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Xiangya Hospital of Central South University , Changsha ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecological surgery, Cancer Hospital of University of Chinese Academy of Sciences , Hangzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking Union Medical College Hospital , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Peking Union Medical College Hospital , Beijing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"Suppl 6","key":"2025031509024642100_CIT0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"2025031509024642100_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","article-title":"Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need","volume":"4","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"issue":"1","key":"2025031509024642100_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2025031509024642100_CIT0004","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025031509024642100_CIT0005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","article-title":"Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin\u00ae) in recurrent ovarian, tubal, or peritoneal cancer: an NRG oncology\/gynecologic oncology group study","volume":"146","author":"Cohn","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2025031509024642100_CIT0006","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000442288","article-title":"CA125 and HE4: Measurement tools for ovarian cancer","volume":"81","author":"Zhao","year":"2016","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"2025031509024642100_CIT0007","doi-asserted-by":"crossref","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"2025031509024642100_CIT0008","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s11033-019-04794-8","article-title":"Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis","volume":"46","author":"Mansha","year":"2019","journal-title":"Mol Biol Rep"},{"issue":"27","key":"2025031509024642100_CIT0009","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025031509024642100_CIT0010","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/cncr.30830","article-title":"Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality","volume":"123","author":"Tomao","year":"2017","journal-title":"Cancer"},{"issue":"suppl_8","key":"2025031509024642100_CIT0011","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2025031509024642100_CIT0012","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Ann Oncol"},{"key":"2025031509024642100_CIT0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer","volume":"77","author":"Le Saux","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2025031509024642100_CIT0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/13543784.2021.1939305","article-title":"Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies","volume":"30","author":"Leung","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2025031509024642100_CIT0015","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Global Oncol"},{"issue":"1","key":"2025031509024642100_CIT0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","article-title":"Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs","volume":"10","author":"Harter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"2025031509024642100_CIT0017","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s007610050307","article-title":"Palliative therapeutische moglichkeiten beim ovarialkarzinom","volume":"4","author":"Meier","year":"1998","journal-title":"Der Onkologe"},{"issue":"6","key":"2025031509024642100_CIT0018","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000421-199412000-00007","article-title":"Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer","volume":"17","author":"Burnett","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2025031509024642100_CIT0019","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-021-04371-6","article-title":"Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma","volume":"89","author":"Wen","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025031509024642100_CIT0020","doi-asserted-by":"crossref","first-page":"909426","DOI":"10.3389\/fonc.2022.909426","article-title":"pegylated liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant treatment for HER2-positive breast cancer patients: a phase II and biomarker study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2025031509024642100_CIT0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13048-020-00736-2","article-title":"Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer","volume":"14","author":"Yuan","year":"2021","journal-title":"J Ovarian Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae194\/60412674\/oyae194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae194\/60412674\/oyae194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:03:06Z","timestamp":1742029386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae194\/7874888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae194","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,4]]},"article-number":"oyae194"}}